Helus Pharma Inc. HELP

HELP Company Overview

Cybin Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health disorders. The company operates within the biotechnology and neuropsychiatric drug development industries, with a primary emphasis on treatments for conditions such as major depressive disorder, generalized anxiety disorder, and other psychiatric illnesses with significant unmet medical need. Cybin’s core strategy centers on combining proprietary psychedelic compounds with drug delivery technologies and therapeutic support protocols intended to improve efficacy, dosing consistency, and patient experience. Its principal value drivers are its investigational drug candidates, intellectual property portfolio, and clinical development pipeline.

The company was founded in 2019 and is headquartered in Toronto, Canada, with operational and research activities extending into the United States and other international markets. Cybin evolved from an early-stage psychedelic research company into a publicly traded clinical biotechnology organization through acquisitions, licensing arrangements, and internal drug development efforts. The company has sought to differentiate itself through shorter-duration psychedelic compounds, novel deuterated molecules, and controlled treatment protocols designed to improve scalability and commercial viability relative to earlier psychedelic-assisted therapy models.